(S)-(−)-colchicine
(S)-(−)-colchicine is the naturally occurring, biologically active stereoisomer of colchicine and the form most commonly associated with the drug’s pharmacological effects.
(S)-(−)-colchicine is the naturally occurring, biologically active stereoisomer of colchicine and the form most commonly associated with the drug’s pharmacological effects. Colchicine is a well-known microtubule assembly inhibitor that binds to β-tubulin (TUBB), disrupting tubulin polymerization and thereby altering cell division, cytoskeletal dynamics, and inflammatory cell function. Because of these properties, it has long been used therapeutically in inflammatory diseases such as gout and is also studied as a probe for microtubule-dependent biology.
Clinically, colchicine has a narrow therapeutic window and significant systemic toxicity, which limits broader use and motivates ongoing work on targeted delivery, dose optimization, and derivative design. In recent research, (S)-(−)-colchicine has also been used as a mechanistic tool in disease models, including models of acute gouty arthritis, cognitive dysfunction, and inflammatory cardiovascular injury, and as a reference compound in formulation and drug-repurposing studies.
Where the papers sit
9 papers from the last 6 months study (S)-(−)-colchicine directly · updated from PubMed 1 Oct 2026
Study type 3 clinical trials · 5 preclinical · 1 unclassified
Themes no clear themes
Those 9 do not share a common subject.
-
Colchicine appears here across unrelated cardiovascular, osteoarthritis, cancer, and drug-delivery questions. Clinical studies test low-dose treatment for coronary microcalcification, hypertension, and knee osteoarthritis, while engineered platforms target myocardial injury and fibrosis. Other papers examine colchicine-binding microtubule inhibitors, activity in methotrexate-resistant choriocarcinoma, and transdermal release prediction. The cluster shares colchicine-centered therapeutic investigation but shows no single biological theme or research direction.
Papers
The 9 papers from the last 6 months that study (S)-(−)-colchicine directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (9)
- Influence of low-dose colchicine on coronary microcalcification activity in patients with diffuse coronary artery disease undergoing coronary artery bypass grafting: protocol for single-centre randomised open-label blinded-endpoint trial (the COL-CABG trial). BMJ open · 15 Sept 2026 PMID 42744364
- CoLchicine for Treatment of OsteoArthritis of the Knee (CLOAK): Clinical and biochemical outcomes from a three-month double-blind, placebo-controlled study. Seminars in arthritis and rheumatism · 1 Sept 2026 PMID 42679472
- Reshaping the cardiac microenvironment: a colchicine-loaded nanoplatform with lesion targeting and matrix penetration for myocardial fibrosis therapy. Biomaterials science · 27 Aug 2026 PMID 42657586
- Drug library screening identifies colchicine and shikonin as therapeutic candidates for methotrexate-resistant choriocarcinoma. Biochemical and biophysical research communications · 20 Jul 2026 PMID 42476068
- Discovery of furan-trimethoxyphenyl hybrids as novel colchicine-binding site inhibitors that induce mitotic catastrophe with potent anti-acute myeloid leukemia effect. Bioorganic chemistry · 19 Jun 2026 PMID 42320118
- In Vitro Release Prediction of Colchicine Transdermal Patch Based on Raman Spectroscopy Imaging and Data-Driven Modeling. AAPS PharmSciTech · 17 Jun 2026 PMID 42310244
- Discovery and Pharmacological Characterization of a Dual-Acting 2-Amino-3-Cyanopyridine Inhibitor Targeting Microtubule Polymerization and GAK. Journal of medicinal chemistry · 16 Jun 2026 PMID 42298883
- Cardiac-homing peptide-targeted colchicine-based drugstores with inhibiting inflammatory response for myocardial infarction improvement. Materials today. Bio · 29 May 2026 PMID 42211057
- A Randomized Trial to Investigate the Effects of Low-Dose Colchicine in Patients with Hypertension: Rationale and Design of the COlchicine and HypERtENsion Trial (COHERENT). Journal of clinical hypertension (Greenwich, Conn.) · 28 May 2026 PMID 42210033
By study type
Clinical trials (3)
- Influence of low-dose colchicine on coronary microcalcification activity in patients with diffuse coronary artery disease undergoing coronary artery bypass grafting: protocol for single-centre randomised open-label blinded-endpoint trial (the COL-CABG trial). BMJ open · 15 Sept 2026 PMID 42744364
- CoLchicine for Treatment of OsteoArthritis of the Knee (CLOAK): Clinical and biochemical outcomes from a three-month double-blind, placebo-controlled study. Seminars in arthritis and rheumatism · 1 Sept 2026 PMID 42679472
- A Randomized Trial to Investigate the Effects of Low-Dose Colchicine in Patients with Hypertension: Rationale and Design of the COlchicine and HypERtENsion Trial (COHERENT). Journal of clinical hypertension (Greenwich, Conn.) · 28 May 2026 PMID 42210033
Preclinical: animal, cell and lab studies (5)
- Reshaping the cardiac microenvironment: a colchicine-loaded nanoplatform with lesion targeting and matrix penetration for myocardial fibrosis therapy. Biomaterials science · 27 Aug 2026 PMID 42657586
- Drug library screening identifies colchicine and shikonin as therapeutic candidates for methotrexate-resistant choriocarcinoma. Biochemical and biophysical research communications · 20 Jul 2026 PMID 42476068
- Discovery of furan-trimethoxyphenyl hybrids as novel colchicine-binding site inhibitors that induce mitotic catastrophe with potent anti-acute myeloid leukemia effect. Bioorganic chemistry · 19 Jun 2026 PMID 42320118
- In Vitro Release Prediction of Colchicine Transdermal Patch Based on Raman Spectroscopy Imaging and Data-Driven Modeling. AAPS PharmSciTech · 17 Jun 2026 PMID 42310244
- Discovery and Pharmacological Characterization of a Dual-Acting 2-Amino-3-Cyanopyridine Inhibitor Targeting Microtubule Polymerization and GAK. Journal of medicinal chemistry · 16 Jun 2026 PMID 42298883
Unclassified: not yet indexed with MeSH (1)
- Cardiac-homing peptide-targeted colchicine-based drugstores with inhibiting inflammatory response for myocardial infarction improvement. Materials today. Bio · 29 May 2026 PMID 42211057
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-06-24. Last written: 2026-07-29 by GPT. Drafted by language models from published abstracts; not medical advice.